cryptocurrency make money, Overview

During the year, there were 461 new indices, and the index investment fever continued to climb. On December 10th, in order to meet the investment demand of diversified indices, CSI Index Co., Ltd. officially released five new indices, including CSI 1000 Growth Index, CSI 1000 Value Index, CSI 2000 Growth Index, CSI 2000 Value Index and CSI 1000 Quality Balance Strategy Index. With the "listing" of the above five indexes, the number of newly-issued indexes reached 461 during the year, covering categories such as strategy, style, scale, industry, theme and other fixed-income indexes; Related index asset classes include stocks, fixed income, funds and futures. At the same time, the secondary market, this year, the heat of indexed investment is also high. Looking forward to the future, with the continuous vigorous growth of market demand and unabated heat, and the precise guidance and strong support from the supervisory level, the indexed investment ecology will become more and more perfect. (Securities Daily)Goldman Sachs: I don't agree that gold can't reach $3,000 under a strong dollar. Goldman Sachs said that we don't agree with the view that the price of gold can't rise to $3,000 per ounce by the end of 2025 when the dollar remains strong for a long time. We predict that gold will reach $3,000 per ounce by the end of 2025, and the reduction of interest rate cuts by the Federal Reserve (rather than the strengthening of the US dollar) is the downside risk of this prediction.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.

Argentine President Millai: Argentina will abolish capital controls next year.Trump appointed TOM BARRACK as the US ambassador to Turkey.The latest monitoring report released by the World Bank shows that Lebanon's GDP will drop by 6.6% in 2024. The latest Lebanon economic monitoring report released by the World Bank on the 10th shows that the real GDP of Lebanon will drop by 6.6% in 2024 due to the influence of lebanon war. According to the report, the large-scale displacement, destruction and the reduction of personal consumption caused by the conflict have had a devastating impact on Lebanon's economy and exacerbated the country's macroeconomic challenges. The report emphasizes that after the upgrading of lebanon war in September this year, Lebanese key industries, including tourism, have been seriously affected.

Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.CITIC Securities: The logic of "grabbing exports" is expected to support the short-term performance of China's exports. According to the CITIC Securities Research Report, in November, China's exports maintained a certain growth rate, exports to emerging markets maintained a high growth rate, and exports of mechanical and electrical products performed brilliantly. In the short term, both CCFI index and SCFI index are on the rise, and the logic of "grabbing exports" is expected to support the short-term performance of China's exports. In the long run, if the United States imposes tariffs on China, China's export performance may be dragged down. However, based on the analysis of the import share structure of the United States, the European Union, Vietnam, Mexico and other economies, we can see that the current pattern of China's trade diversification has improved compared with the last round of Sino-US trade friction, and the trade between emerging markets and China has become closer and closer. The imposition of tariffs by the United States on China may affect the bilateral trade between China and the United States more, and domestic enterprises going to sea and re-exporting trade may still be effective ways to hedge the impact of US tariffs on China.Caoji Group seeks to raise up to HK$ 138 million through Hong Kong IPO. According to the announcement of the Hong Kong Stock Exchange, Caoji Group will issue about 33.3 million shares at a price range of HK$ 3.75 to HK$ 4.15 per share. The company may raise up to HK$ 138 million (US$ 17.8 million) and is expected to start listing on December 19th.